Rituximab-induced vasculitis [3]

Dermatology

Volumn 203, Issue 1, 2001, Pages 83-84

  Dereure, Olivier ^a,b   Navarro, Robert ^a   Rossi, Jean François ^a   Guilhou, Jean Jacques ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ELOI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; FLUDARABINE; INTERLEUKIN 6; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; B CELL LEUKEMIA; BLOOD VESSEL WALL; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; HUMAN; LETTER; LEUKOCYTOSIS; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RASH; VASCULITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; DRUG HYPERSENSITIVITY; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MALE; SKIN DISEASES, VASCULAR; VASCULITIS, HYPERSENSITIVITY;

EID: 0034823982     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051713     Document Type: Letter

References (5)

1. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy
2. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group
3. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
4. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
5. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)